Excerpts from most recent RECOVER webinar on Understanding Metformin Use and Long COVID and ME/CFS Following COVID-19 Infection.
Transcript here.
Dr. Susan Vernon: " So, RECOVER provided this incredible opportunity because of the infrastructure, the longitudinal follow-up in the study, and the large, diverse patient populations necessary to really begin to understand ME/CFS in a way that was previously not possible"
"So again, the opportunity to really study ME/CFS and understand that it is a postinfectious consequence of SARS-CoV-2 infection was great to really increase the awareness in general. So, this is just a very exciting opportunity all the way around. And of course, all the people that we work with in the RECOVER consortium—investigators, patients—I get goosebumps thinking about how important this paper is"
"The RECOVER cohort presents a unique opportunity to explore the biological mechanisms and the natural history of post-COVID ME/CFS, an opportunity that as tragic as the pandemic is, an opportunity that is really an unprecedented opportunity to understand and potentially solve ME/CFS. And it also gives us an incredible opportunity to develop objective biomarkers for diagnosis and severity"
"By understanding Long COVID, we will also gain a significant understanding of the pathophysiology as well as possible treatments for ME/CFS."
"Again, RECOVER has just provided an unprecedented opportunity to understand post-COVID ME/CFS. If you think back to that assessment table, included in that assessment table, all those dots across there all across time, was also the sampling framework that was used during the RECOVER observational study. And there are samples that were taken in the first tier—blood samples, fecal samples, saliva samples—that are ripe for testing and digging deeper into ME/CFS. Because now all the people that we have identified as ME/CFS in RECOVER, those samples are associated with those individuals. So that provides a crazy cool opportunity to dig deeper into biomarker discovery and pathogenesis. And then of course there are the tier 2 and the tier 3 assessments that are going on in RECOVER, which dig a little bit deeper in each tier into the various aspects of the pathophysiology. So, my hope is that now that we’ve identified this particular subset of post-COVID ME/CFS within RECOVER, and the data and the samples that have been collected and the additional assessments that are being done, will just really pull back the curtain on ME/CFS and show us a lot of what’s going on."